ADNeT researchers have analysed blood samples from 400 participants for phospho-tau217+ and compared the results to diagnoses using amyloid and tau-PET. Results of this study show that the phospho-tau217+ blood test has promise as a diagnostic aid for Alzheimer’s disease and for finding clinical trial participants for anti-Alzheimer’s drugs.

Findings will be presented at the Australian Dementia Forum in May and the Alzheimer’s Association International Conference in July.

For more information, contact the Australian Dementia Network at adnet-info@unimelb.edu.au